CureVac and University Medical Center Mainz start Phase 3 clinical trial for COVID-19 Vaccine candidate CVnCoV in Healthcare Workers

This mRNA-based vaccine candidate is an optimised, non-chemically modified mRNA, encoding the pre-fusion stabilised full-length spike protein of the SARS-CoV-2 virus. The study aims to evaluate safety and immunogenicity of CVnCoV administered as a two-dose schedule of 12 µg.

Source:

Biospace Inc.